My Cart

Anti-Glycoprotein E (VZV) Antibody, Human IgG1 (1B10) (MALS verified)

Customer Reviews
Cat. No. / Size
Price
Qty
VZV-M544-100ug
$415.00
VZV-M544-1mg (500ug X 2)
$2735.00
ETA of in-stock products:2 business days
Sub-Total$ 0

Product Details

  • Source

    Anti-Glycoprotein E (VZV) Antibody, Human IgG1 (1B10) is a recombinant chimeric monoclonal antibody expressed in HEK293, which combines the variable region of a mouse monoclonal antibody with human constant domain.

  • Antibody Type

    Recombinant Monoclonal

  • Clone

    1B10

  • Isotype

    Human IgG1, Kappa

  • Host Species

    Mouse

  • Reactivity

    Virus

  • Immunogen

    Recombinant Varicella zoster virus (strain Oka vaccine) Envelope Glycoprotein E (gE) derived from human 293 cells

  • Specificity

    This product is a specific antibody specifically reacts with Glycoprotein E/gE (VZV).

  • Application

    Application
    Recommended Usage
    ELISA
    1:10000-1:200000
  • Purification

    Protein A purified / Protein G purified.

  • Aggregation

    Less than 5%, as determined by SEC-MALS.

  • Concentration

    Please refer to the Certificate of Analysis (CoA).

  • Form

    Lyophilized

  • Formulation

    Lyophilized from a 0.22 μm-filtered solution in PBS (pH 7.4), with trehalose as protectant.

    Please contact us for customized product forms or formulations.

  • Reconstitution

    Please refer to the Certificate of Analysis (CoA) for specific instructions.

  • Shipping

    Lyophilized product is shipped at ambient temperature.

  • Storage

    For long term storage, the product should be stored in a lyophilized state at -20°C or lower.

    Please avoid repeated freeze-thaw cycles.

    This product is stable after storage at:

    1. -20°C to -70°C for 12 months in lyophilized state;
    2. -70°C for 3 months under sterile conditions after reconstitution.
  • Notices

    Product Specific Notices: For research use only.

  • ACRO Quality Management System

    1. QMS(ISO, GMP)
    2. Quality Advantages
    3. Quality Control Process

Customers Also Viewed

Performance Data

  • Bioactivity-ELISA

     Glycoprotein E/gE (VZV) ELISA

    Immobilized Varicella zoster virus (strain Oka vaccine) Envelope Glycoprotein E (gE), His Tag (Cat. No. GLE-V52H3) at 1 μg/mL (100 μL/well) can bind Anti-Glycoprotein E (VZV) Antibody, Human IgG1 (1B10) (Cat. No. VZV-M544) with a linear range of 0.1-1 ng/mL (QC tested).

    Protocol
  •  Glycoprotein E/gE (VZV) ELISA

    Immobilized Varicella zoster virus (strain Oka vaccine) Envelope Glycoprotein E (gE), His Tag (Cat. No. GLE-V52H3) on Anti-Glycoprotein E (VZV) Antibody, Human IgG1 (1B10) (Cat. No. VZV-M544) precoated (0.2 μg/well) plate can bind Biotinylated Monoclonal Anti-Glycoprotein E (VZV) Antibody, Human IgG1 (4G2) (Cat. No. VZV-BLM545)at 0.25 μg/mL (100 μL/well) with a linear range of 0.2-8 ng/mL (Routinely tested).

    Protocol
  • Bioactivity-SPR

     Glycoprotein E/gE (VZV) SPR

    Anti-Glycoprotein E (VZV) Antibody, Human IgG1 (1B10) (Cat. No. VZV-M544) captured on Protein A Chip can bind Varicella zoster virus (strain Oka vaccine) Envelope Glycoprotein E (gE), His Tag (Cat. No. GLE-V52H3) with an affinity constant of 5.63 nM as determined in SPR assay (Biacore 8K) (Routinely tested).

    Protocol

Customer Reviews
Writing Reviews

Background

Varicella-zoster virus (VZV) is a neurotropic virus belonging to the Herpesviridae family. Primary VZV infection causes chickenpox and is followed by a life-long latent infection established mainly in the cranial and dorsal root ganglia. Reactivation of the virus is often associated with shingles (herpes zoster).
Glycoprotein E (gE) is one of the known glycoproteins (gB, gC, gE, gH, gI, gK, gI) of VZV that is most abundantly expressed on the surface of virus and infected cells, playing an important role in viral replication and cell-to-cell spread. The strongly immunogenic gE can provide strong IgG signal in body fluid, which makes it ideal to be developed as an antigen for analysis of IgG antibodies. gE also demonstrates high potency as a vaccine immunogen and is formulated as the single viral envelope protein that constitutes the GSK VZV recombinant subunit vaccine Shingrix®.

Recent Advances

 
Contact Us
Drug Candidate Licensing
More
  • Basic Product Information
  • Product Details
  • Customers Also Viewed
  • Performance Data
  • Customer Reviews
  • Background
Contact Us

[North America]: +1 800-810-0816
[Switzerland]: +41 800 040 012
[Asia & Pacific]: +86 400-682-2521

[North America]: 1 Innovation Way, Newark, DE 19711, USA
[Switzerland]: ACRObiosystems AG, c/o Zug Dammstrasse Centre AG, Dammstrasse 19, 6300 Zug Switzerland